2-(1H-吡唑-1-基)乙酸 | 16034-48-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(1H-吡唑-1-基)乙酸
• 中文别名: 吡唑-1-乙酸；1H-吡唑-1-基乙酸；1-吡唑乙酸
• 英文名称: pyrazol-1-yl-acetic acid
• 英文别名: 2-(1H-pyrazol-1-yl)acetic acid；1H-pyrazol-1-ylacetic acid；pyrazole-1-acetic acid；2-(1-pyrazolyl)-acetic acid；2-pyrazol-1-ylacetic acid
• CAS: 16034-48-3
• 化学式: C₅H₆N₂O₂
• mdl: MFCD00228774
• 分子量: 126.115
• InChiKey: LOSKNFQZTWYZHI-UHFFFAOYSA-N

物化性质

• 熔点：
  171-172 °C
• 沸点：
  301.1±25.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(1H-Pyrazol-1-yl)acetic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(1H-Pyrazol-1-yl)acetic acid
CAS number: 16034-48-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H6N2O2
Molecular weight: 126.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(1H-吡唑-1-基)乙酸 在 sodium hydroxide 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 [(S)-3-phenyl-2-[(2-pyrazol-1-yl)acetylamino]propionylamino]acetic acid
  参考文献：
  名称：

  将（吡唑-1-基）乙酰基和（吡啶-2-基）乙酰基团添加到苯丙胺二肽的末端氨基基团提供 ATCUN 样铜 (II) 结合位点

  摘要：

  (Pyrazol-1-yl) 乙酸 (HL1, 1) 和 (pyridin-2-yl) 乙酸已成功与 Phe-Gly 二肽的末端氨基缩合生成衍生物 PzCH2-Phe-Gly (H3L2 , 7) 和 PyCH2–Phe-Gly (H3L3, 8) 分别含有 ATCUN 样金属离子结合位点。描述了 1 和铜 (II) 配合物 Cu(L1)2(H2O)2 (2) 和 [nBu4N][Cu(L2)] (9) 的晶体结构。配合物 2 具有四边形拉长、Jahn-Teller 扭曲八面体几何形状，配合物 9 是方形平面。7 和 8 的铜 (II) 配合物的结构相似性由它们几乎相同的电子吸收和 EPR 光谱证明。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005)

  DOI：

  10.1002/ejic.200400437
• 作为产物：
  描述：

  2-(1H-吡唑-1-基)乙酸乙酯 在 lithium hydroxide monohydrate 、 水 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 生成 2-(1H-吡唑-1-基)乙酸
  参考文献：
  名称：

  SUBSTITUTED HETEROCYCLIC COMPOUNDS

  摘要：

  本发明涉及式I或XI的取代杂环化合物： 或其药用可接受的盐或N-氧化物或季铵盐，其中所述成员在此提供，并且它们的组合物和使用方法，这些方法是组胺H24受体抑制剂，用于治疗组胺H24受体相关的疾病或疾病，包括例如炎症性疾病或疾病，瘙痒和疼痛。

  公开号：

  US20100240671A1

文献信息

• Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i)
  作者：Markus Klein、Michael Busch、Manja Friese-Hamim、Stefano Crosignani、Thomas Fuchss、Djordje Musil、Felix Rohdich、Michael P. Sanderson、Jeyaprakashnarayanan Seenisamy、Gina Walter-Bausch、Ugo Zanelli、Philip Hewitt、Christina Esdar、Oliver Schadt

  DOI：10.1021/acs.jmedchem.1c00604

  日期：2021.7.22

  acids, which selectively inhibit LMP7 while sparing all other subunits. The exploitation of structural differences between the proteasome subunits culminated in the identification of the highly potent, exquisitely selective, and orally available LMP7 inhibitor 50 (M3258). Based on the strong antitumor activity observed with M3258 in MM models and a favorable preclinical data package, a phase I clinical

  蛋白酶体是泛素依赖性蛋白质降解途径中广泛表达的关键成分，其中包含具有催化活性的亚基（β1、β2 和 β5）。LMP7 (β5i) 是免疫蛋白酶体的一个亚基，是一种主要在造血细胞中表达的诱导型异构体。用于治疗多发性骨髓瘤 (MM) 的临床有效的泛蛋白酶体抑制剂非选择性靶向 LMP7 和组成型蛋白酶体和免疫蛋白酶体的其他亚基，具有相当的效力，这可能会限制这些药物的治疗适用性。在这里，我们描述了新型酰氨基硼酸的发现和基于结构的命中优化，它选择性地抑制 LMP7，同时保留所有其他亚基。对蛋白酶体亚基之间结构差异的开发最终确定了高效能，50 (M3258)。基于 M3258 在 MM 模型中观察到的强大抗肿瘤活性和有利的临床前数据包，在复发/难治性 MM 患者中启动了 I 期临床试验。
• Photoredox Catalysis: 1,4-Conjugate Addition of <i>N</i>-Methyl Radicals to Electron-Deficient Olefins via Decarboxylation of <i>N</i>-Substituted Acetic Acids
  作者：Lakshmaiah Gingipalli、Jeffrey Boerth、David Emmons、Tyler Grebe、Holia Hatoum-Mokdad、Bo Peng、Li Sha、Sharon Tentarelli、Haixia Wang、Ye Wu、XiaoLan Zheng、Scott Edmondson、Ariamala Gopalsamy

  DOI：10.1021/acs.orglett.0c00873

  日期：2020.5.1

  In this report, we describe a new photoredox catalyzed 1,4-conjugate addition of N-substituted acetic acids to electron-deficient olefins via decarboxylative C-C bond formation. This C-C bond formation occurred under mild conditions enabled by visible light irradiation. This transformation facilitated the synthesis of biologically relevant N-substituted heterocyclic structural motifs not readily accessible

  在本报告中，我们描述了一种新的光氧化还原催化 1,4-共轭加成 N-取代的乙酸通过脱羧 CC 键形成缺电子烯烃。这种CC键形成发生在可见光照射的温和条件下。这种转化促进了其他方法不易获得的生物学相关的 N 取代杂环结构基序的合成。CC键形成方案应用于弱亲核杂环，如吲哚、吲唑、咪唑和环状酰胺，以形成功能化的药物样小分子。
• Synthesis of 3-Azabicyclo[3.2.0]heptane-Derived Building Blocks via [3+2] Cycloaddition
  作者：Anton A. Homon、Oleksandr V. Hryshchuk、Serhii Trofymchuk、Oleg Michurin、Yuliya Kuchkovska、Dmytro S. Radchenko、Oleksandr O. Grygorenko

  DOI：10.1002/ejoc.201800972

  日期：2018.11.1

  Synthesis of 3‐azabicyclo[3.2.0]heptane‐derived building blocks via [3+2]cycloaddition of cyclobutene‐1‐carboxylate and azomethine ylide is described. It is shown that the title bicyclic scaffold is a three‐dimensional template which is well‐compatible with lead‐oriented parallel synthesis.

  描述了通过环丁烯-1-羧酸酯和甲亚胺叶立德的[3 + 2]环加成反应合成3-氮杂双环[3.2.0]庚烷的结构单元。结果表明标题双环支架是一个三维模板，与基于铅的平行合成很好地兼容。
• A method for C2 acylation of 1,3-indandiones
  作者：Brian J. Larsen、Robert J. Rosano、Thomas A. Ford-Hutchinson、Allen B. Reitz、Jay E. Wrobel

  DOI：10.1016/j.tet.2018.04.041

  日期：2018.5

  3-indandione scaffold is an important structural motif used in the preparation of a large number of industrial chemical and pharmaceutical compounds. However, few approaches allow for the direct C2 acylation on these building blocks. A method was developed using DMAP and EDCI, which is mild in reactivity, covers a diverse range of carboxylic acid acylating agents, is compatible with electron releasing

  1,3-茚满二酮支架是用于制备大量工业化学和药物化合物的重要结构基序。但是，很少有方法允许在这些构件上直接进行C2酰化。使用DMAP和EDCI开发了一种方法，该方法反应性温和，涵盖了各种羧酸酰化剂，与1,3-茚满二酮配偶体上的电子释放和吸收取代基兼容，并且在极性非质子溶剂中表现良好（由于溶解度原因）该方法干净地提供了25种不同的产物，收率32-96％。
• Structure–Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions
  作者：Jiuyu Liu、David F. Bruhn、Robin B. Lee、Zhong Zheng、Tanja Janusic、Dimitri Scherbakov、Michael S. Scherman、Helena I. Boshoff、Sourav Das、Rakesh、Samanthi L. Waidyarachchi、Tiffany A. Brewer、Begoña Gracia、Lei Yang、John Bollinger、Gregory T. Robertson、Bernd Meibohm、Anne J. Lenaerts、Jose Ainsa、Erik C. Böttger、Richard E. Lee

  DOI：10.1021/acsinfecdis.6b00158

  日期：2017.1.13

  Spectinamides are a novel class of antitubercular agents with the potential to treat drug-resistant tuberculosis infections. Their antitubercular activity is derived from both ribosomal affinity and their ability to overcome intrinsic efflux mediated by the Mycobacterium tuberculosis Rv1258c efflux pump. This study explores the structure–activity relationships through analysis of 50 targeted spectinamides

  Spectinamides是一类新型的抗结核药，具有治疗耐药性结核感染的潜力。它们的抗结核活性来源于核糖体亲和力和克服结核分枝杆菌介导的内在外排的能力RV1258C外排泵。这项研究通过分析50种靶向Sp​​ectinamides探索了结构-活性关系。评价化合物的核糖体翻译抑制作用，Rv1258c外排泵缺陷型和野生型结核菌株中的MIC活性，以及​​在急性肺结核感染模型中的功效。这项研究的结果显示出狭窄的结构-活性关系，与紧密的核糖体结合口袋和克服天然外排的严格结构要求相一致。使用分子动力学模拟对核糖体抑制数据的合理化表明，卤代Spectinamides形成稳定的复合物，与长期观察到的抗生素作用一致。结核分枝杆菌。此处详述的构效关系强调了在抗结核药物设计中必须检查外排介导的耐药性，并证明可以通过合成修饰克服内在排泄。了解此类结构要求的能力产生了多种新的取代的Spectinamides，它们可能